Tenofovir + Lamivudine + Dolutegravir Tablets 300 mg/300 mg/50 mg Suppliers & Bulk Manufacturers

Available Forms: Film-coated tablets

Available Strengths: 300 mg/300 mg/50 mg

Pack Sizes: Bottles of 30 and 90 tablets

Reference Brands: TLD (generic fixed-dose combination)

Category: Anti Viral

Tenofovir + lamivudine + dolutegravir (TLD) is the WHO-preferred once-daily first-line HIV treatment. PharmaTradz sources TLD for tenders, national programmes and importers.

Product Description:

TLD combines three HIV medicines in one tablet: tenofovir disoproxil fumarate and lamivudine, which block the enzyme the virus uses to copy itself, and dolutegravir, which stops the virus inserting its genetic material into human cells. Dolutegravir works quickly and the virus rarely becomes resistant to it, which is why TLD replaced older efavirenz-based regimens.

WHO has recommended TLD as the preferred first-line treatment for adults and adolescents with HIV since 2019, and it is used by millions of people. It is one tablet once a day, with or without food. Kidney function is checked because of tenofovir, and some medicines (such as certain antacids, iron and calcium supplements) must be taken apart from it as they reduce dolutegravir absorption.

Sourcing notes. TLD is a generic-only product made mainly by Indian manufacturers, and most is bought through Global Fund, PEPFAR and national tenders, which usually require WHO prequalification or a US FDA tentative approval. Dolutegravir is supplied under Medicines Patent Pool licences covering most low- and middle-income countries; outside that territory patents may still apply, so we confirm the destination first. Room-temperature storage.